Study | NCT number (trial name) | Phase | N | Regimen | ORR | PFS rate | Median PFS (months) |
---|---|---|---|---|---|---|---|
Zonder 2012 [23] | NCT00425347 (HuLuc63-1701) | 1 | 35a | Elotuzumab (0.5–20 mg/kg) | 0 | – | – |
NCT00742560 (HuLuc63-1703) | 1b | 29b | Elotuzumab (5–20 mg/kg) + Rd | 82 % | – | 32.9 | |
Richardson 2015 [27] | NCT00742560 (HuLuc63-1703) | 2 | 36 | Elotuzumab (10 mg/kg) + Rd | 92 % |  | 32.5c |
37 | Elotuzumab (20 mg/kg) + Rd | 76 % |  | 25.0c | |||
Lonial 2015 [32] | NCT01239797 (ELOQUENT-2) | 3 | 321 | Elotuzumab (10 mg/kg) + Rd | 79 % | 1-year 68 %, 2-year 41 % | 19.4 |
325 | Rd | 66Â % | 1-year 57Â %, 2-year 27Â % | 14.9 | |||
Mateos 2014 [34] | NCT01632150 | 2 | 40 | Elotuzumab (10 mg/kg) + TDd | 40 % | – | – |
Jakubowiak 2012 [35] | NCT00726869 (HuLuc63-1702) | 1 | 28 | Elotuzumab (2.5–20 mg/kg) + V | 48 % |  | 9.46e |
Palumbo 2015 [38] Jakubowiak 2016 [39] | NCT01478048 | 1/2 | 77f | Elotuzumab (10 mg/kg) + VD | 66 % | 1-year 39 %, 2-year 18 % | 9.7 |
75 | VD | 63Â % | 1-year 33Â %, 2-year 11Â % | 6.9 |